Transcranial stimulation for early Alzheimer's disease
Effect of Transcranial Alternating Current Stimulation(tACS) for Early Alzheimer's Disease
This study is testing if a type of brain stimulation can help improve thinking skills in people with early Alzheimer's disease.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 50 Years to 85 Years |
| Sex | All |
| Sponsor | Anhui Medical University Academic / other |
| Locations | 1 site (Hefei, Anhui) |
| Trial ID | NCT06565143 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of transcranial alternating current stimulation (tACS) on patients with early Alzheimer's disease. Participants will undergo cognitive assessments and receive either tACS or sham treatment over a continuous 14-day period. The study employs a double-blind design, ensuring that both participants and researchers are unaware of treatment allocations to minimize bias. Cognitive performance will be evaluated using various standardized tests before and after the intervention to assess the treatment's efficacy.
Who should consider this trial
Good fit: Ideal candidates are individuals diagnosed with early Alzheimer's disease who have mild cognitive impairment and meet specific cognitive assessment criteria.
Not a fit: Patients with moderate to severe Alzheimer's disease or those with significant psychiatric or neurological conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could improve cognitive function in patients with early Alzheimer's disease.
How similar studies have performed: While the use of tACS in cognitive disorders is emerging, this specific application in early Alzheimer's disease is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Subject diagnosed with early Alzheimer's disease or related diseases according to NIA-AA criteria. 2. Subjects must have a MMSE score between 10 and 27,indicating mild cognitive impairment or dementia. 3. CDR score ≤ 2. 4. Subject under treatment by IAChE for at least 3 months. 5. psychotropic treatments are tolerated if they were administered and unchanged for at least 3 months. Exclusion Criteria: 1. CDR \> 2 2. Any history or clinical signs of other severe psychiatric illnesses (like major depression,psychosis or obsessive compulsive disorder). 3. History of head injury,stroke,or other neurologic disease. 4. Organic brain defects on T1 or T2 images. 5. History of seizures or unexplained loss of consciousness. 6. Implanted pacemaker,medication pump,vagal stimulator,deep brain stimulator. 7. Family history of medication refractory epilepsy. 8. History of substance abuse within the last 6 months.
Where this trial is running
Hefei, Anhui
- Anhui Medical University — Hefei, Anhui, China (Recruiting)
Study contacts
- Study coordinator: Kai Wang, PhD
- Email: wangkai1964@126.com
- Phone: +86-0551-62922263
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.